• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …

Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Guidelines Liaison; cHFSA Representative; dASE Representative; eHRS Representative;
fSCMR Representative; gAATS Representative; hSCAI Representative; and iFormer Joint …

Several treatments have demonstrated safety and effectiveness in the treatment of patients
with hypertrophic cardiomyopathy; however, no drug has been shown to modify the natural …

: hypertrophic cardiomyopathy, obstructive hypertrophic cardiomyopathy, hypertrophic
cardiomyopathy phenocopies, sarcomeric mutations, familial genetic screening, sudden …